Denosumab added to immunotherapy for liver cancer with bone spread
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a medicine called denosumab, which strengthens bones, when added to your usual immunotherapy for liver cancer that has spread to the bones. The goal is to see if this combination can help control the cancer and protect your bones.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with hepatocellular carcinoma (the most common type of liver cancer).
- The cancer has spread to your bones (confirmed by imaging like CT, MRI, or bone scan).
- You have not had immunotherapy (such as PD-1/PD-L1 inhibitors) before.
- You have not used denosumab or bisphosphonates for cancer-related bone disease in the last 6 months.
- You are generally in good health (able to do daily activities) and have adequate liver function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving focused local treatment (like radiation or surgery) after a combination of two drugs, sintilimab and lenvatinib, can help control advanced liver cancer that has spread to a few other places. The goal is to see if this approach can shrink tumors and possibly extend life.
This trial tests a combination of an immunotherapy drug (PD-1 inhibitor), a bone-strengthening drug (denosumab), and chemotherapy for people with advanced or spread non-squamous non-small cell lung cancer that does not have certain genetic changes. The goal is to see if this combination helps shrink tumors and control the disease.
This trial tests a combination of radiation (SBRT), an immunotherapy drug (PD-L1 inhibitor), and a targeted therapy (lenvatinib) for people with liver cancer that has spread to abdominal lymph nodes. It may be an option if you haven't taken certain immunotherapies before or if your cancer progressed after them.
This trial tests a drug called Tislelizumab (an immunotherapy) combined with chemotherapy for people with advanced NSCLC who have already been helped by a different immunotherapy. It's a second-line option for those who did well on their first immunotherapy but now need another treatment.
This trial tests a new drug combination for liver cancer that has progressed after standard treatment. The goal is to see if the combination can shrink tumors or slow the cancer's growth.
This trial tests whether adding a liver-directed treatment to standard systemic therapy can improve outcomes for people with liver cancer that cannot be removed. It may help shrink tumors or slow the disease while on current treatment.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.